Live feed
Filing
SCHEDULE 13D
SCHEDULE 13D0001193125-26-052946·Agomab Therapeutics NV
Schedule 13D ownership disclosure
AgomAb Therapeutics NV
Common Shares, no nominal value per share ("Common Shares") · CUSIP: 00860C102
Event date: 2026-02-09
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- LSP 7 Cooperatieve U.A.Reported CIK 0001876264
Shares: 5,141,992 · Class: 10.6%
- LSP 7 Management B.V.
Shares: 5,141,992 · Class: 10.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-26-052946
- Form type
- SCHEDULE 13D
- Filer
- Agomab Therapeutics NV
- CIK
- CIK 2020932
- Filed
- Feb 17, 2026
- Reporting period
- Feb 09, 2026
- Description
- Schedule 13D beneficial ownership